Treatment algorithm

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer

ONGOING

all patients

Back
1st line – 

treatment of underlying cause

No specific treatment of chronic pyelonephritis is possible; however, patients should have underlying causes (e.g., infection, obstruction) treated appropriately to prevent further damage. In both children and adults, recurrent infections resulting from anatomical abnormalities are a major factor in the development of chronic pyelonephritis and renal failure. In chronic interstitial nephritis, the primary aetiological factors are vesicoureteral reflux and obstruction.[11]

Back
Plus – 

nephrectomy and antibiotics

Treatment recommended for ALL patients in selected patient group

Urgent urological consultation is essential in the management of these patients.

The main treatment of this chronic destructive inflammatory process is surgical.

Medical treatment does not cure this disease, but because most patients are diabetic, good glucose control and treatment of infection with gram-negative cover are recommended. Antibiotic treatment includes third-generation cephalosporins, fluoroquinolones, extended-spectrum penicillins, aminoglycosides, and carbapenem antibiotics.

In the setting of increasing drug resistance in uropathogens, the following newer antibiotics are approved in some countries for use in adults with complicated urinary tract infection (UTI) caused by susceptible organisms who have limited or no alternative options: meropenem/vaborbactam, plazomicin, cefiderocol, and imipenem/cilastatin/relebactam.[44][45][46]​​

Because of the destructive nature of the lesions, xanthogranulomatous pyelonephritis (XGP) may be mistaken for renal cell carcinoma on radiological images (e.g., CT scan). The correct diagnosis may not be made until the patient undergoes surgery.

The treatment of this rare infectious disease is surgical; this generally includes partial or, typically, total nephrectomy.[16][25] The disease rarely involves both kidneys and has not been shown to progress serially from one kidney to the other, and surgical resection is curative.[16]

Treatment course: 10-14 days. A repeat urine culture should be performed at least 48 hours after the last antibiotic dose in order to document resolution of the UTI.

Primary options

ceftriaxone: 1 g intravenously every 24 hours

OR

ciprofloxacin: 200-400 mg intravenously every 12 hours

OR

gentamicin: 3-5 mg/kg/day intravenously

OR

ampicillin/sulbactam: 3 g intravenously every 6 hours

More

OR

piperacillin/tazobactam: 3.375 g intravenously every 6-8 hours

More

OR

imipenem/cilastatin: 250-500 mg intravenously every 6-8 hours

More

OR

ertapenem: 1 g intravenously every 24 hours

OR

ceftazidime/avibactam: 2.5 g intravenously every 8 hours

More

Secondary options

meropenem/vaborbactam: 4 g intravenously every 8 hours

More

OR

plazomicin: 15 mg/kg intravenously every 24 hours

OR

cefiderocol: 2 g intravenously every 8 hours

OR

imipenem/cilastatin/relebactam: 1.25 g intravenously every 6 hours

More
Back
Plus – 

percutaneous drainage, antibiotics, and supportive therapy

Treatment recommended for ALL patients in selected patient group

Urgent urological consultation is essential in the management of these patients.

If patients are haemodynamically stable, percutaneous drainage or stent placement to relieve obstruction may be the preferred option, together with antibiotics.[17][18][49] If no clinical improvement is noted within 24 to 48 hours, a repeat CT scan should be obtained, and nephrectomy considered.[1]

Most patients are acutely ill, and stabilisation in the emergency department with adequate fluid resuscitation and tissue oxygenation has been shown to decrease morbidity and improve mortality.[26]

Intravenous antibiotics are given for this severe infection; duration of treatment depends on clinical response to therapy. Antibiotic treatment includes third-generation cephalosporins, fluoroquinolones, extended-spectrum penicillins, aminoglycosides, and carbapenem antibiotics.

In the setting of increasing drug resistance in uropathogens, the following newer antibiotics are approved in some countries for use in adults with complicated urinary tract infection (UTI) caused by susceptible organisms who have limited or no alternative options: meropenem/vaborbactam, plazomicin, cefiderocol, and imipenem/cilastatin/relebactam.[44][45][46]​​

Treatment course: 10-14 days. A repeat urine culture should be performed at least 48 hours after the last antibiotic dose in order to document resolution of the UTI.

Primary options

ceftriaxone: 1 g intravenously every 24 hours

OR

ciprofloxacin: 200-400 mg intravenously every 12 hours

OR

gentamicin: 3-5 mg/kg/day intravenously

OR

ampicillin/sulbactam: 3 g intravenously every 6 hours

More

OR

piperacillin/tazobactam: 3.375 g intravenously every 6-8 hours

More

OR

imipenem/cilastatin: 250-500 mg intravenously every 6-8 hours

More

OR

ertapenem: 1 g intravenously every 24 hours

OR

ceftazidime/avibactam: 2.5 g intravenously every 8 hours

More

Secondary options

meropenem/vaborbactam: 4 g intravenously every 8 hours

More

OR

plazomicin: 15 mg/kg intravenously every 24 hours

OR

cefiderocol: 2 g intravenously every 8 hours

OR

imipenem/cilastatin/relebactam: 1.25 g intravenously every 6 hours

More
Back
Consider – 

nephrectomy

Additional treatment recommended for SOME patients in selected patient group

Urgent urological consultation is essential in the management of these patients.

In the past, nephrectomy was recommended in all patients. However, patients who undergo urgent nephrectomy in the face of sepsis are significant surgical risks.

Patients who have no clinical improvement with drainage and antibiotics within 24 to 48 hours, or who are severely ill or septic, need nephrectomy.[1][51]

Operative treatment, such as nephrectomy and drainage, along with antibiotics has been shown to decrease the mortality rate.[51]

back arrow

Choose a patient group to see our recommendations

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer

Use of this content is subject to our disclaimer